$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals Reports...
$Eton Pharmaceutical(ETON.US$ Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
-- Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13(th) straight quarter of sequential product sales growth
-- Acquired PKU GOLIKE(R), launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400
-- Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13(th) straight quarter of sequential product sales growth
-- Acquired PKU GOLIKE(R), launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
